• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Health Services Research >The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with medication treated type 2 diabetes: A retrospective cross-sectional study using a national pharmacy claims database
【24h】

The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with medication treated type 2 diabetes: A retrospective cross-sectional study using a national pharmacy claims database

机译：爱尔兰老年患者接受药物治疗的2型糖尿病的慢性合并症患病率和原料成本：使用国家药房索赔数据库的回顾性横断面研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Comorbidity in patients with diabetes is associated with poorer health and increased cost. The aim of this study was to investigate the prevalence and ingredient cost of comorbidity in patients ≥?65 years with and without medication treated type 2 diabetes using a national pharmacy claims database. Methods The Irish Health Service Executive Primary Care Reimbursement Service pharmacy claims database, which includes all prescribing to individuals covered by the General Medical Services scheme, was used to identify the study population (≥?65 years). Patients with medication treated type 2 diabetes (T2DM) were identified using the prescription of oral anti-hyperglycaemic agents alone or in combination with insulin as a proxy for disease diagnosis. The prevalence and ingredient prescribing cost of treated chronic comorbidity in the study population with and without medication treated T2DM were ascertained using a modified version of the RxRiskV index, a prescription based comorbidity index. The association between T2DM and comorbid conditions was assessed using logistic regression adjusting for age and sex. Bootstrapping was used to ascertain the mean annual ingredient cost of treated comorbidity. Statistical significance at p? Results In 2010, 43165 of 445180 GMS eligible individuals (9.7%) were identified as having received medication for T2DM. The median number of comorbid conditions was significantly higher in those with T2DM compared to without (median 5 vs. 3 respectively; p? Conclusions Individuals with T2DM were more likely to have a higher number of treated comorbid conditions than those without and this was associated with higher ingredient costs. This has important policy and economic consequences for the planning and provision of future health services in Ireland, given the expected increase in T2DM and other chronic conditions.
机译：背景糖尿病患者的合并症与健康状况较差和成本增加有关。这项研究的目的是使用国家药房药品索赔数据库调查≥65岁≥65岁有无药物治疗的2型糖尿病患者的合并症患病率和成分成本。方法使用爱尔兰卫生服务执行局初级保健报销服务药房索赔数据库（包括所有由普通医疗服务计划覆盖的处方）来识别研究人群（≥65岁）。使用单独的口服抗高血糖药或与胰岛素组合作为疾病诊断的替代药物，可以确定患有药物治疗的2型糖尿病（T2DM）的患者。使用改良版的RxRiskV指数（一种基于处方的合并症指数），可以确定接受和不使用药物治疗的T2DM的研究人群中慢性合并症的患病率和成分处方费用。 T2DM与合并症之间的关联使用年龄和性别进行逻辑回归评估。自举法用于确定治疗合并症的平均年原料成本。 p的统计显着性？结果2010年，在445180名符合GMS的个体中，有43165名被确认为接受过T2DM药物治疗。患有T2DM的合并症的中位数显着高于未患有T2DM的合并症（中位数分别为5和3; p？结论）患有T2DM的个体与未患有合并症的患者相比，患有合并症的人数更高考虑到预计会增加T2DM和其他慢性病，这对爱尔兰的未来卫生服务的计划和提供具有重要的政策和经济影响。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号